View Older Stories View More Recent Stories

Jul 8, 2020 05:01PM The New England Journal of Medicine Publishes Final Results from Phase 1/2 Study of Tofersen for a Genetic Form of ALS
Jul 8, 2020 05:01PM The New England Journal of Medicine Publishes Final Results from Phase 1/2 Study of Tofersen for a Genetic Form of ALS
Jul 8, 2020 07:35AM Biogen (BIIB) Completes Submission of BLA to FDA for Aducanumab as Treatment for Alzheimer's Disease
Jul 8, 2020 07:30AM Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer’s Disease
Jul 8, 2020 07:30AM Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer’s Disease
Jun 10, 2020 07:32AM Biogen (BIIB) Announces New Results From Landmark NURTURE Study Show That Pre-Symptomatic SMA Patients Treated With SPINRAZA Continue to Demonstrate Sustained Benefit From Treatment
Jun 10, 2020 07:30AM New Results From Landmark NURTURE Study Show That Pre-Symptomatic SMA Patients Treated With SPINRAZA® (nusinersen) Continue to Demonstrate Sustained Benefit From Treatment
Jun 10, 2020 07:30AM New Results From Landmark NURTURE Study Show That Pre-Symptomatic SMA Patients Treated With SPINRAZA® (nusinersen) Continue to Demonstrate Sustained Benefit From Treatment
Jun 4, 2020 07:35AM Biogen (BIIB) Presents Positive Phase 2 Cutaneous Lupus Erythematosus Data at EULAR
Jun 4, 2020 07:30AM Biogen Presents Positive Phase 2 Cutaneous Lupus Erythematosus (CLE) Data at European E-Congress of Rheumatology (EULAR) 2020
Jun 4, 2020 07:30AM Biogen Presents Positive Phase 2 Cutaneous Lupus Erythematosus (CLE) Data at European E-Congress of Rheumatology (EULAR) 2020
May 28, 2020 07:30AM Biogen and MIT Launch New Virtual Learning Lab for High School Students Historically Underrepresented in Science
May 28, 2020 07:30AM Biogen and MIT Launch New Virtual Learning Lab for High School Students Historically Underrepresented in Science
May 19, 2020 07:30AM New Data at AAN Showcase Biogen’s Commitment to Advancing Innovation in MS
May 19, 2020 07:30AM New Data at AAN Showcase Biogen’s Commitment to Advancing Innovation in MS
May 18, 2020 07:31AM Biogen (BIIB) Announces New SPINRAZA Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of SMA Patients
May 18, 2020 07:30AM New SPINRAZA® (nusinersen) Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of Spinal Muscular Atrophy (SMA) Patients
May 18, 2020 07:30AM New SPINRAZA® (nusinersen) Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of Spinal Muscular Atrophy (SMA) Patients
May 18, 2020 03:00AM Samsung Bioepis Announces 24-week Interim Results from a Phase 3 Trial of SB11, Proposed Ranibizumab Biosimilar
Apr 20, 2020 05:45PM Biogen Releases 2019 Corporate Responsibility Report Demonstrating Continuous Progress Across Environmental, Social and Governance Metrics
Apr 20, 2020 05:45PM Biogen Releases 2019 Corporate Responsibility Report Demonstrating Continuous Progress Across Environmental, Social and Governance Metrics
Apr 16, 2020 07:30AM Biogen, Broad Institute of MIT and Harvard, Partners HealthCare Launch Consortium to Build and Share a COVID-19 Biobank
Apr 16, 2020 07:30AM Biogen, Broad Institute of MIT and Harvard, Partners HealthCare Launch Consortium to Build and Share a COVID-19 Biobank
Apr 2, 2020 07:35AM Biogen (BIIB) Reports First Patient Treated with Higher Dose of SPINRAZA (nusinersen) in Phase 2/3 DEVOTE Study
Apr 2, 2020 07:30AM Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study
Apr 2, 2020 07:30AM Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study
Mar 16, 2020 04:09PM Biogen Foundation Commits $10 Million to Support COVID-19 Relief Efforts in the U.S. and Around the World
Mar 16, 2020 04:08PM Biogen Foundation Commits $10 Million to Support COVID-19 Relief Efforts in the U.S. and Around the World
Feb 27, 2020 04:38PM Sangamo Therapeutics (SGMO), Biogen (BIIB) Enter Gene Regulation Therapies Collaboration
Feb 27, 2020 04:06PM Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases
Feb 27, 2020 04:06PM Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases
Feb 27, 2020 04:06PM Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases
Jan 13, 2020 07:31AM Biogen (BIIB) to Acquire Novel Clinical Stage Asset with Application in Alzheimer's Disease and Parkinson's Disease from Pfizer Inc. (PFE)
Jan 13, 2020 07:30AM Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease from Pfizer Inc.
Jan 13, 2020 07:30AM Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease from Pfizer Inc.
Jan 8, 2020 07:30AM Behind the Seizure® Program Further Expands Access to Genetic Testing for Children to Speed the Diagnosis of Genetic Epilepsy
Dec 19, 2019 07:08AM Ionis Pharmaceuticals (IONS) licenses investigational Alzheimer's therapy to Biogen (BIIB)
Dec 13, 2019 07:31AM Biogen (BIIB) Phase 2 PASSPORT study of gosuranemab for PSP misses primary endpoint
Dec 13, 2019 07:30AM Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy
Dec 13, 2019 07:30AM Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy
Dec 3, 2019 07:32AM Biogen (BIIB) Reports Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE)
Dec 3, 2019 07:30AM Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE)
Dec 3, 2019 07:30AM Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE)
Nov 22, 2019 07:31AM Biogen (BIIB) Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY Compared to TECFIDERA
Nov 22, 2019 07:30AM Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate)
Nov 22, 2019 07:30AM Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate)
Nov 21, 2019 07:37AM Biogen (BIIB) Reports Complete Enrollment of Global Phase 3 Gene Therapy Study for Inherited Retinal Disorder
Nov 21, 2019 07:30AM Biogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study for an Inherited Retinal Disorder
Nov 21, 2019 07:30AM Biogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study for an Inherited Retinal Disorder
Nov 6, 2019 07:46AM Samsung Bioepis Enters into Commercialization Agreement for Next-Generation Biosimilar Candidates
View More Recent Stories View Older Stories